DMAC

DiaMedica Therapeutics Inc. (DMAC) | Rumor.io

DiaMedica Therapeutics

DMAC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,300

Bullish sentiment (50-day avg)33%

Price to earnings ratio-11.9

Market capitalization448.7M

Earnings per share-0.72

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-32.8M

Social

What share of all stock conversation is about DMAC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 8

DiaMedica Therapeutics Inc. ($DMAC) has been highlighted by Leon Cooperman as a value play despite his overall bearish market outlook.
DiaMedica will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9th.
Cooperman's endorsement of $DMAC has generated interest and buying activity, with some investors considering it a good opportunity.

Generated by AI

Sentiment

Of the messages about DMAC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.83% -1.72
Bearish	—	—	—	4.17% +1.72

Bullish· Jul 7

$DMAC is ridiculously cheap and oversold, making it a last chance to buy under $4.
The stock has a total addressable market and great risk-to-reward, making it an attractive investment opportunity.
$DMAC is expected to bounce soon, with some buyers entering the market and a possible MACD crossover on the daily chart.

Bearish· Jun 29

DiaMedica Therapeutics Inc.'s ($DMAC) stock price crashed despite positive clinical trial results from the REDUX study.
The company's stock has not recovered from a significant drop, with some investors suggesting it may be due to the influence of Seeking Alpha's articles.
DiaMedica's ($DMAC) stock price may be devaluing in the short term, according to a predictive algorithm, and some investors are expecting a further drop to around $4.00.

Generated by AI

Topics

Of the messages about DMAC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	50.98%
Announcements	—	—	—	35.29%
Earnings	—	—	—	2.61%
Analysts	—	—	—	11.11%
Controversies	—	—	—	0%
Macro	—	—	—	0%

Jun 26

DiaMedica Therapeutics is expanding its DM199 program into preeclampsia, a new indication for the treatment.
The company has entered into a private placement agreement to issue 4.72M shares at $2.50 per share, raising $11.8M in gross proceeds.
DiaMedica plans to use the net proceeds from the private placement to fund its clinical and product development activities, including the pivotal Phase 2/3 ReMEDy2 trial for acute ischemic stroke.

Generated by AI

Community

Of the messages about DMAC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	47.68%
Newcomers	—	0%	0%	52.32%

Regulars· Jun 21

DiaMedica Therapeutics Inc. has announced a $37.5 million private placement to support its clinical trials.
The FDA has removed the clinical hold on DiaMedica's Phase 2/3 trial for DM199, a drug for ischemic stroke, allowing the trial to proceed.
DiaMedica's stock has experienced significant price movements, including a 6.91% gain in the pre-market and an 11.11% drop in the last 4 minutes, with a current price of $4.

Newcomers· Jul 7

The company's cash reserves of $41 million may alleviate concerns about its current valuation, with a market cap of approximately $35 million and a negative enterprise value.
Analysts from Oppenheimer, Lake Street Capital, and Craig Hallum have downgraded or lowered their price targets for $DMAC, citing various reasons.
The stock's recent performance has been negative, with a 36.14% dip today, a -0.49% weekly decline, and a -15.13% monthly loss, with a weekly volatility of +4.51%.

Generated by AI

MINNEAPOLIS, September 02, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York.

27d agoYahoo Finance

Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

1mo agoYahoo Finance

DiaMedica (DMAC) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy

DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1mo agoYahoo Finance

DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration

Detailed price information for Diamedica Therapeutics Inc (DMAC-Q) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...

DMAC reports statistically significant blood pressure reductions in late-onset preeclampsia, progresses FGR study, and maintains cash runway through 2027 despite increased R&D spending.

1mo agoYahoo Finance

Also Discussed

Investors talking about DMAC also mention

#	Name	Attention
1	Axsome Therapeutics IncAXSM	0.01%0
2	SCPH - scPharmaceuticals Inc.	——
3	Achieve Life Sciences, Inc.ACHV	0%new
4	PRTK - Paratek Pharmaceuticals, Inc.	——
5	CWBR - CohBar, Inc.	——
6	Seres Therapeutics Inc.MCRB	0%0
7	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
8	Entera Bio Ltd.ENTX	0%new
9	Krystal Biotech, Inc.KRYS	0%0
10	Arcutis Biotherapeutics, Inc.ARQT	0%+0

DiaMedica Therapeutics Inc.

Healthcare
Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases. Its current pipeline is centered on DM199, a recombinant form of human tissue kallikrein-1 being studied for acute ischemic stroke, preeclampsia, fetal growth restriction, and other conditions linked to impaired blood flow. The company also advances DM300, a recombinant human ulinastatin candidate in preclinical development for inflammatory disorders. DiaMedica Therapeutics serves the neuroscience, women’s health, renal, and inflammatory disease areas through therapies designed to address significant unmet medical needs. Headquartered in Minneapolis, Minnesota, DiaMedica Therapeutics Inc. operates as a specialized biotech platform focused on recombinant protein-based drug development.

Website

Location

301 Carlson Parkway

Minneapolis, MN, 55305

United States

Social

What share of all stock conversation is about DMAC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 8

DiaMedica Therapeutics Inc. ($DMAC) has been highlighted by Leon Cooperman as a value play despite his overall bearish market outlook.
DiaMedica will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9th.
Cooperman's endorsement of $DMAC has generated interest and buying activity, with some investors considering it a good opportunity.

Generated by AI

Sentiment

Of the messages about DMAC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.83% -1.72
Bearish	—	—	—	4.17% +1.72

Bullish· Jul 7

$DMAC is ridiculously cheap and oversold, making it a last chance to buy under $4.
The stock has a total addressable market and great risk-to-reward, making it an attractive investment opportunity.
$DMAC is expected to bounce soon, with some buyers entering the market and a possible MACD crossover on the daily chart.

Bearish· Jun 29

DiaMedica Therapeutics Inc.'s ($DMAC) stock price crashed despite positive clinical trial results from the REDUX study.
The company's stock has not recovered from a significant drop, with some investors suggesting it may be due to the influence of Seeking Alpha's articles.
DiaMedica's ($DMAC) stock price may be devaluing in the short term, according to a predictive algorithm, and some investors are expecting a further drop to around $4.00.

Generated by AI

Topics

Of the messages about DMAC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	50.98%
Announcements	—	—	—	35.29%
Earnings	—	—	—	2.61%
Analysts	—	—	—	11.11%
Controversies	—	—	—	0%
Macro	—	—	—	0%

Jun 26

DiaMedica Therapeutics is expanding its DM199 program into preeclampsia, a new indication for the treatment.
The company has entered into a private placement agreement to issue 4.72M shares at $2.50 per share, raising $11.8M in gross proceeds.
DiaMedica plans to use the net proceeds from the private placement to fund its clinical and product development activities, including the pivotal Phase 2/3 ReMEDy2 trial for acute ischemic stroke.

Generated by AI

Community

Of the messages about DMAC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	47.68%
Newcomers	—	0%	0%	52.32%

Regulars· Jun 21

DiaMedica Therapeutics Inc. has announced a $37.5 million private placement to support its clinical trials.
The FDA has removed the clinical hold on DiaMedica's Phase 2/3 trial for DM199, a drug for ischemic stroke, allowing the trial to proceed.
DiaMedica's stock has experienced significant price movements, including a 6.91% gain in the pre-market and an 11.11% drop in the last 4 minutes, with a current price of $4.

Newcomers· Jul 7

The company's cash reserves of $41 million may alleviate concerns about its current valuation, with a market cap of approximately $35 million and a negative enterprise value.
Analysts from Oppenheimer, Lake Street Capital, and Craig Hallum have downgraded or lowered their price targets for $DMAC, citing various reasons.
The stock's recent performance has been negative, with a 36.14% dip today, a -0.49% weekly decline, and a -15.13% monthly loss, with a weekly volatility of +4.51%.

Generated by AI

DiaMedica Therapeutics

Social

Sep 8

Sentiment

Bullish· Jul 7

Bearish· Jun 29

Topics

Jun 26

Community

Regulars· Jun 21

Newcomers· Jul 7

News

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet

DiaMedica (DMAC) Q2 2026 Earnings Call Transcript

All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy

DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration

DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...

Also Discussed

DiaMedica Therapeutics Inc.

Company Information

Location

News

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet

DiaMedica (DMAC) Q2 2026 Earnings Call Transcript

All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy

DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration

DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...

Also Discussed

Social

Sep 8

Sentiment

Bullish· Jul 7

Bearish· Jun 29

Topics

Jun 26

Community

Regulars· Jun 21

Newcomers· Jul 7